Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Janisch

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patientsE E Vokes, M J Ratain, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Sequential therapy with dacarbazine and carmustine: a phase I studyR B Mitchell, M E Dolan, L Janisch, et al.
Pharmacogenetics|February 1, 1996
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and genderM J Ratain, R Mick, L Janisch, et al.
Cancer|October 1, 1994
Prognostic factors for survival in patients treated in phase I clinical trialsL Janisch, R Mick, R L Schilsky, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2000
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrationsB C Goh, G F Fleming, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|June 10, 1998
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)S Mani, L Iyer, L Janisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1992
Suramin: is adaptive control necessary?K Kobayashi, E E Vokes, K Stefansson, et al.
Clinical Pharmacology and Therapeutics|November 1, 1991
Paradoxical relationship between acetylator phenotype and amonafide toxicityM J Ratain, R Mick, F Berezin, et al.
Cancer Research|May 15, 1993
Phase I study of amonafide dosing based on acetylator phenotypeM J Ratain, R Mick, F Berezin, et al.
Archives of Dermatology|January 1, 1996
Keratoacanthomas and skin neoplasms associated with suramin therapyK Kobayashi, D S Pezen, N J Vogelzang, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patientsE E Vokes, M J Ratain, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Sequential therapy with dacarbazine and carmustine: a phase I studyR B Mitchell, M E Dolan, L Janisch, et al.
Pharmacogenetics|February 1, 1996
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and genderM J Ratain, R Mick, L Janisch, et al.
Cancer|October 1, 1994
Prognostic factors for survival in patients treated in phase I clinical trialsL Janisch, R Mick, R L Schilsky, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2000
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrationsB C Goh, G F Fleming, L Janisch, et al.
Cancer Chemotherapy and Pharmacology|June 10, 1998
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)S Mani, L Iyer, L Janisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1992
Suramin: is adaptive control necessary?K Kobayashi, E E Vokes, K Stefansson, et al.
Clinical Pharmacology and Therapeutics|November 1, 1991
Paradoxical relationship between acetylator phenotype and amonafide toxicityM J Ratain, R Mick, F Berezin, et al.
Cancer Research|May 15, 1993
Phase I study of amonafide dosing based on acetylator phenotypeM J Ratain, R Mick, F Berezin, et al.
Archives of Dermatology|January 1, 1996
Keratoacanthomas and skin neoplasms associated with suramin therapyK Kobayashi, D S Pezen, N J Vogelzang, et al.
Pageof 3